HIV: Drug resistance and nursing practice

American Journal of Nursing

Volumn 101, Issue 6, 2001, Pages 30-35

  Esch, Julie Funesti ^b   Frank, Stacy V ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; DRUG MONITORING; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; NURSING; NURSING ASSESSMENT; REVIEW; TREATMENT FAILURE; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; DRUG RESISTANCE; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NURSING ASSESSMENT; TREATMENT FAILURE;

EID: 0040620226     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200106000-00017     Document Type: Article

References (27)

1. Sowell RL. AIDS care nursing: looking forward, thinking back. J Assoc Nurses AIDS Care 2000;11(1):22-3.
2. Katzenstein DA, et al. HIV therapeutics: confronting adherence. J Assoc Nurses AIDS Care 1997;8(Suppl):46-58.
3. Mellors JW. Clinical applications of HIV drug resistance testing. International AIDS Society 1999 Oct 5; 13-20.
4. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267(5197):483-9.
5. Brown AJ, Richman DD. HIV-1: gambling on the evolution of drug resistance? Nat Med 1997;3(3):268-71.
6. Klaus BD, Grodesky MJ. Understanding the emergence of antiretroviral resistance in HIV/AIDS treatment. Nurse Pract 1999;24(10):95-7.
7. Eigen M. Viral quasispecies. Sci Am 1993;269(1):42-9.
8. Perelson AS, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271(5255):1582-6.
9. Bartlett JG. Antiretroviral therapy. In: Medical management of HIV infection. Baltimore: Johns Hopkins University Press; 1998. p. 63-6.
10. Haynes RB, et al. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979.
11. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In: Fauci AS, et al., editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 1701-856.
12. Kuritzkes DR. HIV pathogenesis and viral markers. In: HIV/AIDS Clinical Management; 2000. vol. 2. Medscape. http://hiv.medscape.com/Medscape/HIV/ClinicalMgmt/CM. v02/public/index.CM.v02.html.
13. Hoyt MJ. Selected adult laboratory values. In: Casey KM, et al., editors. ANAC's core curriculum for HIV/AIDS nursing. Philadelphia: Nursecom; 1996. p. 421-3.
14. Flexner C. HIV genotype and phenotype - arresting resistance? JAMA 2000;283(18):2442-4.
15. Johnson VA. HIV resistance to antiretroviral drugs. Improving the Management of HIV Disease 1998;6:8-12.
16. Deeks SG, Zolopa AR. Choosing and using resistance assays. In: The Medscape HIV/AIDS: annual update 2000. http://www.medscape.com/Medscape/HrV/AnnualUpdate/2000/mha.update05.06.deeks/ mha05.deeks-01.html.
17. Hammer SM. Strategies for treatment and management of antiretroviral failures. Improving the Management of HIV Disease 1999;7:12-5.
18. Williams AB, et al. Medication adherence in HIV infected women. Presented at the International Conference on AIDS and STDs; Geneva; 1998.
19. Gallant JE. Antiretroviral therapy: initial strategies. In: The Medscape HIV/AIDS: annual update 2000; 2000. http://www.medscape.com/Medscape/HIV/AnnualUpdate/2000/mha.update05.04.gallant/ mha05.gallant-01.html.
20. Parkin NT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000;14(18):2877-87.
21. Hirsch MS, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000;283(18):2417-26.
22. Hirsch MS, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998;279(24):1984-91.
23. Kuritzkes DR. Resistance testing in antiretroviral management. Improving the Management of HIV Disease 1999;7:4-7.
24. Kuritzkes DR. Clinical implications of antiretroviral resistance. In: HIV/AIDS Clinical Management; 2000. vol. 13. Medscape. http://medscape.com/Medscape/HIV/ClinicalMgmt/CM.v13/public/index-CM.v13.html.
25. Carpenter CC, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283(3):381-90.
26. Albrecht MA, et al. Management of antiretroviral therapy: recommendations of the International AIDS Society - USA Panel. Topics in HIV Medicine 2001;9(1):13-45.
27. Kitahata MM, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334(11):701-6.